BioSpace News Archive

Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, announced its intention to offer and sell $100 million of shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement.

Technological advancements in healthcare infrastructure, increasing R&D investments, and rising public awareness of diabetes about sports medicines are some key factors expected to drive market growth.

According to Emergen Research, the global nutrigenomics market size was USD 389.4 Million in 2020 and is expected to reach USD 1,289.7 Million in 2028 and register a revenue CAGR of 16.2% during the forecast period, 2021-2028.

The rising need to outsource analytical testing services for decreased manufacturing costs and augmented operational efficiency is a key market growth driver.

The global temperature monitoring systems market size is expected to reach USD 6.6 billion by 2028 at a CAGR of 4.2%, according to a new report by Reports and Data.

The global UV/Visible Spectroscopy Market is expected to be valued at USD 1.49 billion by 2028 from USD 1.00 Billion in 2020, registering a CAGR of 5.1% during the forecast period.

Covalon Technologies Ltd., an advanced medical technologies company, will release its Q4 and year end Fiscal 2021 financial results on Monday, December 13, 2021 before markets open.

Samsung Bioepis Co., Ltd. today announced that SB3 (ONTRUZANT®, trastuzumab-dttb), a biosimilar to Herceptin® (trastuzumab), demonstrated comparable long-term survival results between SB3 and reference trastuzumab (TRZ) after a median follow-up of 68 months from the randomization of the SB3 Phase 3 study.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new clinical data for the HER2-targeted bispecific antibody, zanidatamab, in heavily pretreated HER2-positive breast cancer.

Bobby Sheng, chairman of Bora Pharmaceuticals, announced a partnership with Taishin Healthcare Limited Partnership at the 2021 Biotech Investor Forum, whereby the two parties will jointly invest up to NT$3 billion to target forward-looking contract development and manufacturing organizations and contract research organizations, in response to the development trend that is taking place worldwide.